SafeCure Safeguard Repressor-Mediated Cell Fate Lock Gene Therapy for Glioblastoma
- Coordinator
- Deutsches Krebsforschungszentrum Heidelberg, Germany
- Runs
- 1 January 2027 to 30 June 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335277
What the project is doing
In the project's own words, from its summary on CORDIS.
Glioblastoma (GBM) remains the most lethal primary brain tumour, with a median survival of 15 months despite maximal treatment, unchanged in two decades. Over 95% of clinical trials have failed. The fundamental reason is cell fate plasticity: GBM cells switch between phenotypic states to evade any single therapy. No current approach addresses the regulatory machinery that permits this switching. SafeCure will translate two discoveries from ERC Starting Grant SafeFate into a first-in-class gene therapy.
The first is MYT1L, a neuronal transcription factor we identified as a ""safeguard repressor"" that locks GBM cells in a stable, low-plasticity state by suppressing alternative fate programmes. In orthotopic mouse models that faithfully recapitulate human GBM, MYT1L already extends survival significantly as monotherapy. To achieve safe, targeted re-expression of MYT1L exclusively in tumour cells, we developed a second innovation: 96 tumour-specific enhancers (TSEs) identified through our AI framework (scDORI), which drive gene expression in GBM cells while remaining silent in healthy brain.
Delivered via adeno-associated virus (AAV) and combined with standard chemotherapy, this creates a ""lock-and-kill"" strategy: MYT1L locks cells in a vulnerable state
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI